Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc gamma R functions.
about
Comparative Evaluation of the Chemical Stability of 4 Well-Defined Immunoglobulin G1-Fc GlycoformsMolecular cloning, characterization, genomic organization and promoter analysis of the α1,6-fucosyltransferase gene (fut8) expressed in the rat hybridoma cell line YB2/0The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.IgG subclasses and allotypes: from structure to effector functions.Aleuria Aurantia Lectin (AAL)-reactive immunoglobulin G rapidly appears in sera of animals following antigen exposureThe emerging importance of α-L-fucose in human breast cancer: a review.Prophylactic anti-D preparations display variable decreases in Fc-fucosylation of anti-D.The impact of microcarrier culture optimization on the glycosylation profile of a monoclonal antibody.Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers.Preserved antiviral adaptive immunity following polyclonal antibody immunotherapy for severe murine influenza infection.Anti-rhesus D prophylaxis in pregnant women is based on sialylated IgG antibodiesStructure and function of immunoglobulinsGlycoFi's technology to control the glycosylation of recombinant therapeutic proteins.Protective role of mouse IgG1 in cryoglobulinaemia; insights from an animal model and relevance to human pathology.Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.Impact of Glycosylation on Effector Functions of Therapeutic IgGProtective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques.Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities.Functional in vitro studies of recombinant human immunoglobulin G and immunoglobulin A anti-D.Clinical severity of visceral leishmaniasis is associated with changes in immunoglobulin g fc N-glycosylation.Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector Functions.Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16.A human anti-D monoclonal antibody selected for enhanced FcgammaRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies.Improved in vitro and in vivo activity against CD303-expressing targets of the chimeric 122A2 antibody selected for specific glycosylation pattern.Activating and inhibitory Fcγ receptors in immunotherapy: being the actor or being the targetSialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener's)Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis
P2860
Q28820826-684F4272-2AE4-4840-943D-5CBED6DCD156Q33786180-40E7B93A-CBA3-48A1-970F-DC0AFDCB916FQ33911286-C1EEA1F5-A0D3-47CC-B3BB-709A0F485AC2Q34368678-DD4D02BF-BD1B-4111-81EC-18FA2A0964DCQ34424997-4B796160-AE68-4EA0-ABCD-AF4E8AA0239FQ35172546-D4438EEA-E267-4BDD-B525-C171769B855DQ35262648-7F6E8D6A-B0D8-47A5-BB1C-0BB6158EE682Q36670313-DD6F2171-401A-46B3-96F8-318BAE8AC6D4Q36903911-7B5B4976-69A2-42A8-8B20-64AC6B6A4D5FQ37067663-4F086805-37E5-4506-A23B-DEA7FC281290Q37311301-93645DD9-7EB3-4C7F-B4B0-FE5541A1736CQ37696721-97E235B4-21D4-48D6-9E2B-E20569293682Q38028654-C51FFA3E-FE7F-45EE-A627-B3BC2D7E56DBQ38593866-AC8ED2BB-BC90-457D-B939-D77A6115F784Q38718049-4D7571F8-50FA-4741-B475-1C87A9DBFEC9Q38818688-31E55A99-5684-40E1-A14D-406B8CEA59EDQ39265150-29DA887F-CC49-479A-9D15-98E3BABC7EE1Q40077073-6C835A57-0DD7-42A0-B8FD-929D9D858CFCQ40242103-A079CE86-F596-4DF9-ACE9-A8A7BA40D223Q41622831-AED839C7-DD0F-4717-954B-89327D4AD1F6Q42173120-784A2A38-851D-4001-8283-B8E06636D516Q46731906-AB9E52EC-67B2-42F1-94AD-D54C7FD6E944Q50659071-B19A2F8E-B439-4EBC-BE22-66F6C06C7B76Q52648918-698C842D-1C63-4609-AB9F-27A1707FB267Q57583344-1234FD71-D1C5-4625-AB3B-4B35F03CCD1AQ58004245-27EF7E7D-0850-4D87-AF4B-8C4A65E48CF6Q58234756-A12B32F8-968D-43E3-88AD-C21581B18623
P2860
Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc gamma R functions.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Selection of a human anti-RhD ...... hibitory Fc gamma R functions.
@en
type
label
Selection of a human anti-RhD ...... hibitory Fc gamma R functions.
@en
prefLabel
Selection of a human anti-RhD ...... hibitory Fc gamma R functions.
@en
P2093
P50
P1433
P1476
Selection of a human anti-RhD ...... hibitory Fc gamma R functions.
@en
P2093
Annie Regenman
Arnaud Glacet
Christine Gaucher
Christophe de Romeuf
Dominique Bourel
Jean-Luc Meterreau
Jean-Luc Teillaud
Mark P Hogarth
Nadine Fernandez
Nicolas Bihoreau
P304
P356
10.1016/J.CLIM.2005.10.008
P577
2005-12-05T00:00:00Z